top of page
The EVOLUTION Trial for Psoriatic Arthritis is being conducted at several centers across the United States.
​
The purpose of the study is to determine the most effective treatment for people with psoriatic arthritis (PsA) who have either stopped responding to or didn't respond to a TNFi (Tumor Necrosis Factor inhibitor) such as Humira, Enbrel, Cimzia or Remicade. Specifically, we are studying whether, after loss of response or lack of response to a TNFi, switching to an IL23i (Interleukin-23 inhibitor) is more effective than switching to a different TNFi.
INTERESTED?
Please complete this contact form!
​
Someone on our study team will follow up with you as soon as possible!
bottom of page